Drugs

SHAREHOLDER ALERT: Robbins LLP Announces That FibroGen, Inc. (FGEN) is Being Sued for Misleading Shareholders

Thursday, April 15, 2021 - 7:11pm

FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease and cancer.

Key Points: 
  • FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease and cancer.
  • On February 11, 2020, FibroGen announced that the FDA had completed its filing review of its NDA for roxadustat.
  • FibroGen acknowledged that it could no longer conclude that roxadustat reduces the risk of cardiovascular events or hospitalization when compared to a currently approved anemia injection used as a control.
  • Shareholders pay no fees or expenses.\nContact us to learn more:\n'

China Bevacizumab Market Report 2021-2025 Featuring Roche Pharma (AVASTIN) Qilu Pharmaceutical (Ankeda) & Innovent Biologics (BYVASDA) - ResearchAndMarkets.com

Thursday, April 15, 2021 - 3:02pm

b'The "Investigation Report on the Chinese Bevacizumab Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe sales of Bevacizumab in China will continue to grow due to market expansion.

Key Points: 
  • b'The "Investigation Report on the Chinese Bevacizumab Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe sales of Bevacizumab in China will continue to grow due to market expansion.
  • After the medical insurance negotiations in 2017, the price of AVASTIN decreased from CNY5176 to CNY1998.
  • AVASTIN, the original research drug (developed by Roche Pharma), was approved in China in 2010.
  • In addition to Roche Pharma, Qilu Pharmaceutical and Innovent Biologics are the other two manufacturers in the Chinese market.\nUntil June 2020, six companies have submitted go-public applications for Bevacizumab.

Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Bevacizumab Biosimilar in the Russian Federation

Thursday, April 15, 2021 - 10:40am

HD204 is currently in Phase III clinical development with active recruitment ongoing within the pivotal efficacy and safety trial SAMSON-II.

Key Points: 
  • HD204 is currently in Phase III clinical development with active recruitment ongoing within the pivotal efficacy and safety trial SAMSON-II.
  • Positive results were previously reported from the Phase I clinical trial (SAMSON-I) which evaluated the pharmacokinetics, safety and immunogenicity of HD204 to Avastin\xc2\xae.\nThe partnership arrangement includes the exclusive rights for Pharmapark to commercialize the Bevacizumab biosimilar in the Russian Federation, leveraging the company\xe2\x80\x99s strong sales and marketing capabilities and experience in successfully bringing new biosimilars to market.
  • Whilst the terms of the deal are not being disclosed, Prestige BioPharma will assume responsibility for product commercial supply out of its manufacturing facilities in Osong, Korea, while Pharmapark will be responsible for local registration, sales and marketing in the Russian Federation with the option to manufacture the product in Russian Federation in line with the Russian import substitution strategy.\nThis agreement expands upon the existing collaboration between Prestige BioPharma and Pharmapark LLC with the companies signing a license agreement in July 2019 for Prestige BioPharma\xe2\x80\x99s Herceptin\xc2\xae biosimilar.\nLisa S. Park, CEO of Prestige BioPharma, commented: \xe2\x80\x9cWe are very pleased to further extend our partnership with Pharmapark to commercialize our second biosimilar program in the Russian Federation.
  • Bevacizumab biosimilar candidate will be an excellent addition to our growing biosimilar portfolio\xe2\x80\x9d.\n"

Colorado Cannabis Edibles Front Runner TasteBudz Expands Portfolio, Launching ebb

Thursday, April 15, 2021 - 3:03pm

b'The innovative minds behind the leading Colorado cannabis-infused gummy brand, TasteBudz , announced today the launch of ebb , a fast-acting THC dissolvable powder using nano-encapsulating technology.

Key Points: 
  • b'The innovative minds behind the leading Colorado cannabis-infused gummy brand, TasteBudz , announced today the launch of ebb , a fast-acting THC dissolvable powder using nano-encapsulating technology.
  • ebb is water-soluble, fast-acting, low in sugar, gluten-free and vegan.\nebb pays homage to its Earth-centered name\xe2\x80\x94inspired by the ebb and flow of the ocean\xe2\x80\x94by featuring sustainability-minded packaging.
  • Throughout 2021, ebb will continue to launch new cannabinoid products and expand across Colorado.
  • With its fast-acting effects and functional ingredients like electrolytes and vitamin C, ebb pairs perfectly with outdoor activities, exercise recovery and self-care routines.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005274/en/\n'

Global Vasomotor Symptoms of Menopause (Hot Flashes) Disease Clinical Trials Review, H1 2021 Featuring 10 Key Players & Respective Trials - ResearchAndMarkets.com

Wednesday, April 14, 2021 - 4:34pm

b'The "Vasomotor Symptoms of Menopause (Hot Flashes) Disease - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Vasomotor Symptoms of Menopause (Hot Flashes) Disease - Global Clinical Trials Review, H1, 2021" provides an overview of Vasomotor Symptoms of Menopause (Hot Flashes) Clinical trials scenario.

Key Points: 
  • b'The "Vasomotor Symptoms of Menopause (Hot Flashes) Disease - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Vasomotor Symptoms of Menopause (Hot Flashes) Disease - Global Clinical Trials Review, H1, 2021" provides an overview of Vasomotor Symptoms of Menopause (Hot Flashes) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Vasomotor Symptoms of Menopause (Hot Flashes).\nReport includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).\nThe report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.\nReport provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status\nThe report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company\nThe report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment\nAids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials\nFacilitates clinical trial assessment of the indication on a global, regional and country level\n'

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

Wednesday, April 14, 2021 - 9:16pm

Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China.

Key Points: 
  • Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China.
  • In HCC patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated pneumonitis occurred in 10% (5/49) of patients.
  • In patients receiving OPDIVO monotherapy in Checkmate 040, immune-mediated hepatitis requiring systemic corticosteroids occurred in 5% (8/154) of patients.
  • In Checkmate 142 in MSI-H/dMMR mCRC patients receiving OPDIVO with YERVOY (n=119), serious adverse reactions occurred in 47% of patients.

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed COVID Drug

Wednesday, April 14, 2021 - 3:03pm

b"Cyclica , the partner of choice for data driven drug discovery, in connection with leading Canadian research institutions, has predicted a repurposing drug, capmatinib, with evidence that it attenuates the impact of coronavirus.

Key Points: 
  • b"Cyclica , the partner of choice for data driven drug discovery, in connection with leading Canadian research institutions, has predicted a repurposing drug, capmatinib, with evidence that it attenuates the impact of coronavirus.
  • \xe2\x80\x9cOur business model has always relied on tight collaboration with partner institutions, accelerated by our AI drug discovery platform.
  • To learn more about Cyclica\xe2\x80\x99s drug discovery platform, please visit https://www.cyclicarx.com/ .\nFrom Molecule to medicine, Cyclica embraces the complexity of disease.
  • To learn more about Cyclica and how we partner, please visit www.cyclicarx.com\nRyerson University is Canada's leader in innovative, career-oriented education.

Pyramid Biosciences Announces Leadership Team Expansion

Wednesday, April 14, 2021 - 12:30pm

Dr. Lestini brings over a decade of early- and late-stage clinical development leadership experience in Oncology, including the design, execution and submissions leading to the first global approvals of OPDIVO\xc2\xae (nivolumab, anti-PD1).

Key Points: 
  • Dr. Lestini brings over a decade of early- and late-stage clinical development leadership experience in Oncology, including the design, execution and submissions leading to the first global approvals of OPDIVO\xc2\xae (nivolumab, anti-PD1).
  • \xe2\x80\x9cWe are looking forward to Dr. Lestini\xe2\x80\x99s leadership of our clinical programs during this important growth stage of our company.\xe2\x80\x9d\n\xe2\x80\x9cI am excited to be joining Pyramid Biosciences during this exciting phase for the company,\xe2\x80\x9d said Dr. Lestini.
  • Mr. Wasserman comes to Pyramid Biosciences with nearly 25 years of corporate legal experience, having previously served as both general counsel as well as a partner at multiple law firms.
  • Prior to Pyramid Biosciences, Mr. Wasserman was with Curcio Mirzaian Sirot, a northeast regional law firm where he served as a partner and chairman of its Corporate and Securities practice.

United States Insulin Injection Pen Market Report 2021: $5.5 Billion Growth, Trends and Forecasts to 2027 - ResearchAndMarkets.com

Tuesday, April 13, 2021 - 1:50pm

b'The United States market for the insulin injection pen market is expected to touch US$ 5.5 billion by the year-end of 2027.\nA Comprehensive List of Key Market Players Along with the Analysis of their Current Insulin Injection Pen Portfolios, Business Overview, and Current Development\n'

Key Points: 

b'The United States market for the insulin injection pen market is expected to touch US$ 5.5 billion by the year-end of 2027.\nA Comprehensive List of Key Market Players Along with the Analysis of their Current Insulin Injection Pen Portfolios, Business Overview, and Current Development\n'

Pamos, a California-Born Cannabis Spirit, Launches in Los Angeles

Tuesday, April 13, 2021 - 2:00pm

Pamos is a premium quality, non-alcoholic cannabis spirit infused with THC, CBD, and plant terpenes and is now available for pre-orders at www.pamos.com in Los Angeles.

Key Points: 
  • Pamos is a premium quality, non-alcoholic cannabis spirit infused with THC, CBD, and plant terpenes and is now available for pre-orders at www.pamos.com in Los Angeles.
  • With the belief that a good time shouldn\xe2\x80\x99t be a gamble, Pamos speaks to conscious consumers who want to satisfy their social needs without sacrificing their wellness goals.
  • The THC in the Pamos spirits provides a sense of calm, while the CBD is included to relax one\xe2\x80\x99s body.
  • Pamos can be enjoyed on the rocks or you can tap into your inner mixologist to make it your own.